Fondazione Humanitas per la Ricerca

Fondazione Humanitas per la Ricerca
Name	Fondazione Humanitas per la Ricerca
Founded	2004
Founder	Giovanni Macciotta; Humanitas Research Hospital
Type	Research foundation
Headquarters	Milan
Area served	Italy
Focus	Biomedical research, Clinical trials, Translational medicine

Fondazione Humanitas per la Ricerca is an Italian biomedical research foundation associated with Humanitas Research Hospital and located near Milan. It operates as a hub for clinical and translational research linking academic institutions such as the University of Milan and hospitals including Istituto Nazionale dei Tumori (Milan) with international networks like the European Society for Medical Oncology and the World Health Organization. The foundation supports investigator-initiated studies, multicenter trials, and basic science programs in collaboration with pharmaceutical companies, nonprofit organizations, and consortia across Europe, North America, and Asia.

History

Founded in 2004, the foundation emerged alongside the expansion of Humanitas Research Hospital and the development of affiliated research units such as the Humanitas Clinical and Research Center and the IRCCS designation system. Early partnerships involved institutions like Istituto Clinico Humanitas and research groups from the University of Pavia, the University of Turin, and the University of Milan Bicocca. Over successive phases the foundation established links with the European Research Council, the Italian Ministry of Health, regional authorities in Lombardy, and international entities including the European Molecular Biology Organization and the Howard Hughes Medical Institute. Key milestones reflect collaborations with pharmaceutical companies such as Roche, Novartis, Pfizer, and Bristol-Myers Squibb, and participation in multicenter initiatives coordinated by groups like the European Organization for Research and Treatment of Cancer.

Mission and Objectives

The foundation’s mission aligns with translational aims promoted by organizations such as the National Institutes of Health, the European Commission, and the Wellcome Trust: accelerate bench-to-bedside research, foster precision medicine, and improve patient outcomes in areas including oncology, cardiology, immunology, and metabolic diseases. Objectives emphasize creating synergies with academic departments at the University of Milan School of Medicine, training programs linked to the European Society of Cardiology Academy, and innovation pipelines interfacing with technology firms like IBM and Philips Healthcare. Strategic goals include securing grants from the Fondazione Cariplo and engaging in public–private initiatives similar to those run by the Innovative Medicines Initiative and the Bill & Melinda Gates Foundation.

Research Programs and Centers

Research themes mirror priorities set by organizations such as the European Cancer Organisation, the American Association for Cancer Research, and the American Heart Association. Core programs encompass oncology units collaborating with European Institute of Oncology, cardiometabolic research linked to the Cardiovascular Research Foundation, immuno-oncology labs engaging with the International Agency for Research on Cancer, and genomics platforms cooperating with institutes like the Wellcome Sanger Institute and the European Bioinformatics Institute. Centers include clinical departments analogous to the Dana-Farber Cancer Institute and basic science laboratories modeled on the Max Planck Institute for Molecular Genetics. Platforms for translational science interface with biobanks comparable to those at the UK Biobank and imaging cores similar to facilities at the Cleveland Clinic.

Clinical Trials and Translational Research

The foundation coordinates phase I–III clinical trials registered with authorities such as the European Medicines Agency and the Italian Medicines Agency. Trial portfolios have included oncology studies aligned with consortia like the European Society for Medical Oncology]-sponsored networks, immunotherapy trials in partnership with companies such as AstraZeneca and Merck & Co., and cardiology studies reflecting methodologies from the ClinicalTrials.gov registry standards. Translational research projects integrate approaches favored by the Translational Research Working Group and implement diagnostics comparable to assays developed at the Broad Institute and the Wellcome Trust Sanger Institute. Patient-reported outcomes and real-world evidence initiatives draw on frameworks from the International Society for Pharmacoeconomics and Outcomes Research.

Governance and Funding

Governance structures resemble those used by major research foundations such as the Gordon and Betty Moore Foundation and involve boards including representatives from Humanitas Research Hospital, academic partners like the Vita-Salute San Raffaele University, and clinical leaders with experience at institutions such as Sant'Orsola-Malpighi Hospital. Funding sources combine competitive grants from entities including the European Commission Horizon 2020 program, philanthropic support from donors akin to Fondazione Cariplo and private endowments, as well as industry-sponsored research agreements with GlaxoSmithKline and Johnson & Johnson. Financial oversight aligns with compliance norms referenced by the Organisation for Economic Co-operation and Development and audit practices seen at the European Court of Auditors.

Collaborations and Partnerships

The foundation’s network spans academic partners such as the University of Bologna, Sapienza University of Rome, University of Turin, and Politecnico di Milano for biomedical engineering projects. International collaborations involve research centers like the Karolinska Institutet, University College London, Johns Hopkins University, Harvard Medical School, and hospitals including the Mayo Clinic and the Massachusetts General Hospital. European partnerships include working groups within the European Society of Cardiology, European Society for Medical Oncology, and consortia funded by the European Innovation Council. Industry collaborations have included biotech firms such as Genentech, Amgen, Regeneron, and diagnostics companies such as Roche Diagnostics.

Impact and Recognition

The foundation has contributed to peer-reviewed publications appearing in journals like The Lancet, Nature Medicine, Journal of Clinical Oncology, Circulation, and Cell. Its researchers have presented at conferences including the American Society of Clinical Oncology Annual Meeting, the European Society of Cardiology Congress, and the American Association for Cancer Research meetings. Awards and recognitions mirror honors granted by bodies such as the European Research Council, the Associazione Italiana per la Ricerca sul Cancro, and national science prizes similar to the Premio Galileo. The foundation’s outputs influence clinical guidelines produced by organizations like the European Society of Medical Oncology and contribute data to registries maintained by entities such as the European Society of Cardiology and the World Health Organization.

Category:Medical research foundations in Italy